Noninvasive Imaging of CD206-Positive M2 Macrophages as an Early Biomarker for Post-Chemotherapy Tumor Relapse and Lymph Node Metastasis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Tumor relapse after initial regression post-chemotherapy is a major challenge in cancer treatment, as it usually leads to local-regional recurrence or inoperable distant metastasis.M2 macrophages diminish the tumor-inhibitory effect of chemotherapy and correlate with distant metastasis and poor prognosis.In this study, we investigated whether molecular imaging of M2 macrophages could serve as an early biomarker for tumor relapse after chemotherapy and tumor lymph node metastasis in preclinical mouse models.Methods: We developed M2 macrophage-targeted probes for near-infrared fluorescence (NIRF) imaging and single-photon emission computed tomography (SPECT) using an anti-CD206 monoclonal antibody.The specific targeting capacity and potential applications of the NIRF and SPECT probes were investigated in subcutaneous tumor and lymph node metastasis models of 4T1 murine breast cancer.Results: M2 macrophage infiltration was significantly increased in the 4T1 tumors that later underwent relapse but not in non-relapsing 4T1 tumors after cyclophosphamide treatment.Through NIRF imaging and SPECT using our synthesized probes, the infiltration of M2 macrophages in relapsing tumors and tumor lymph node metastasis could be sensitively detected.Importantly, early prediction of tumor relapse by molecular imaging of M2 macrophages resulted in an effective eradication of tumors upon combination with additional radiotherapy.Conclusion: Our findings demonstrate that M2 macrophage-targeted imaging allows for noninvasively predicting post-chemotherapy tumor relapse and sensitively detecting the metastatic lymph nodes in vivo.This imaging strategy could provide a better understanding of cancer progression, enable early prediction of tumor resistance, and have implications on the rational design of cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 3×
“TAMs play an essential role in tumor progression by stimulating angiogenesis, tumor cell invasion and metastasis, and suppressing anti-tumor immunity [3].”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“TAMs generally express an M2-like phenotype with tumor promoting functions [7].”
BackgroundInfluence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022 · cited 1×
“Clinical evidence has shown that high TAM numbers correlate with poor prognosis in patients with various cancers [8].”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy
Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F.-F., O'Sullivan, B., He, Z., Peng, Y., Tan, A.-C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2385 · Cited by 886
Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung
Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S., & Perlman, H. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0086ma · Cited by 838 · cited 1×
“Notably, CD206 is expressed in several normal organs such as the liver and lung [29, 30], which might partially explain the higher uptake of 125I-αCD206 compared to 125I-IgG in these organs.”
BackgroundAhn, G.-O., Tseng, D., Liao, C.-H., Dorie, M. J., Czechowicz, A., & Brown, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911378107 · Cited by 347 · cited 1×
“Increased M2 macrophage infiltration stimulates tumor relapse after chemotherapy by promoting vascular reconstruction and immunoregulation [2, 17-19].”
BackgroundTumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Tang, X. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.024 · Cited by 276 · cited 2×
“The tumor invasion- and metastasis-promoting effects of M2 macrophages have been reported in several studies [31, 36, 37] and verified in our adoptive M2 macrophage transfer as well as ZA-based macrophage depletion experiments.”
Background
Cited by
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Qin, Z., Ren, T., Zhou, H., Zhang, X., He, L., Li, Z., Zhang, X., & Yuan, L. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202201541 · Cited by 140
Tumor‑associated macrophages in lung cancer: Friendly or evil? (Review)
Xu, F., Wei, Y., Tang, Z., Liu, B., & Dong, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11518 · Cited by 67
“recent large cohort clinical studies have reported a close correlation between the infiltration of M2‐macrophages, poor response to chemotherapy, and poor clinical outcomes (73,74).”
Background
Metadata
- Authors
- Zhang, C., Yu, X., Gao, L., Zhao, Y., Lai, J., Lu, D., Bao, R., Jia, B., Zhong, L., Wang, F., & Liu, Z.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2017
- Volume
- 7
- Issue
- 17
- Pages
- 4276-4288
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2767140964
- Cited by
- 113
- References
- 11
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.